Roivant Sciences shares leapt 22.0% in pre-open trading following an announcement from its Pulmovant unit that topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease - PH-ILD - were positive. The condition is progressive and life-threatening and remains a high unmet medical need.
The study readout was presented at the European Respiratory Society International Congress 2026 by Professor Marc Humbert of Universit e9 Paris-Saclay, a recognized authority in pulmonary hypertension, a detail that added scientific weight to the topline disclosure.
In tandem with the Phase 2 result, Roivant said it has initiated the Phase 3 PHrontier study of mosliciguat in PH-ILD and that enrollment is already underway. Management framed the move as an immediate escalation toward registrational testing, signaling confidence in the Phase 2 data and accelerating the clinical pathway that could lead to regulatory review.
Mosliciguat is described by the company as a potential first-in-class inhaled soluble guanylate cyclase activator, representing a differentiated mechanism of action in a disease area where therapeutic options are limited. The combination of a novel delivery route and a new pharmacologic class factors into the company’s strategic positioning for the asset.
Roivant also convened a dedicated investor webcast and call at 8:00 a.m. ET today to discuss the PHocus findings, an event that drew additional attention from institutional investors during the pre-market session. Management commentary and the formal presentation helped focus investor analysis on both the clinical readout and the implications for development timelines.
The mosliciguat update arrives amid a broader period of pipeline progress for Roivant. The company’s subsidiary Priovant secured FDA approval for LISRAYA (brepocitinib) for dermatomyositis in late August, marking a milestone as Roivant moves into commercial-stage biopharma operations.
Market reaction was dramatic: the pre-market surge pushed ROIV well above its prior 52-week high of $37.97. The move occurred against a mixed wider market background - the NASDAQ was roughly flat while the S&P 500 and Dow Jones were modestly negative - indicating the jump was driven by company-specific catalysts rather than broad market momentum.
Taken together, the positive Phase 2 topline, the immediate pivot to a Phase 3 program, and the company e2 80 99s recent FDA approval success produced one of the largest single-session gains for ROIV in recent memory. Investors appear to be repricing the company to reflect a significantly expanded addressable market across both its pulmonary and autoimmune franchises.
What this means in brief
- Positive Phase 2 data and a rapid Phase 3 start for mosliciguat have driven a substantial pre-market rally in Roivant stock.
- The presentation by Professor Marc Humbert at a major respiratory congress contributed scientific credibility to the readout.
- Roivant e2 80 99s recent FDA approval of LISRAYA supports its transition toward a commercial-stage biopharma company.
Investors and market participants will be watching upcoming enrollment milestones in the PHrontier study and any additional detail from Pulmovant on safety and full efficacy measures as those data are disclosed. For now, the immediate market response underscores the value investors place on both positive clinical data and clear plans to advance to registrational studies.